Hepatitis C care delivery practices among buprenorphine prescribers and non-prescribers: results from a survey of Washington state primary care providers.

IF 3.2 2区医学 Q1 SUBSTANCE ABUSE

Addiction Science & Clinical Practice Pub Date : 2025-09-24 DOI:10.1186/s13722-025-00603-9

Jocelyn R James, Amelia M Mohabir, Claire B Simon, Allison Cole, Emalie Huriaux, Jon Stockton, Julien Rouvere, Judith I Tsui

{"title":"Hepatitis C care delivery practices among buprenorphine prescribers and non-prescribers: results from a survey of Washington state primary care providers.","authors":"Jocelyn R James, Amelia M Mohabir, Claire B Simon, Allison Cole, Emalie Huriaux, Jon Stockton, Julien Rouvere, Judith I Tsui","doi":"10.1186/s13722-025-00603-9","DOIUrl":null,"url":null,"abstract":"Background: Hepatitis C infection (HCV) and opioid use disorder (OUD) are syndemic in the U.S., thus primary care providers (PCPs) who treat OUD by prescribing buprenorphine can play key roles to advance HCV elimination targets. We compared HCV screening and treatment among PCPs who do and do not prescribe buprenorphine in Washington (WA) State.Methods: This study utilized a cross-sectional survey of PCPs in WA State, designed to characterize HCV care delivery practices and experiences/attitudes toward HCV. In this study, the independent variable was self-reported buprenorphine prescribing, and the main outcomes were (1) guideline-concordant HCV screening and (2) directly providing treatment for HCV. We used descriptive statistics to describe respondent characteristics. We used logistic regression to assess the association between buprenorphine prescribing status and HCV screening and treatment outcomes.Results: Our sample included 73 PCPs, of whom 55% prescribe buprenorphine. We found that 25% of buprenorphine prescribers directly treated HCV. There was over a 2x greater relative odds that buprenorphine prescribers would correctly screen for HCV relative to non-prescribers (OR = 2.24; 95% CI: 0.67-8.18, p = .20) and a nearly 2.5x greater relative odds that they would treat HCV relative to non-prescribers (OR = 2.42; 0.72-9.61; p = .17), although both findings were not statistically significant.Conclusion: In a sample of PCPs in WA state, buprenorphine prescribers compared to non-prescribers appear more likely to screen for and directly treat HCV, yet only a minority treat HCV. Interventions are needed to enhance HCV guideline-concordant care among these and all PCPs on the frontlines of caring for persons with OUD.","PeriodicalId":54223,"journal":{"name":"Addiction Science & Clinical Practice","volume":"20 1","pages":"75"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction Science & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13722-025-00603-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatitis C infection (HCV) and opioid use disorder (OUD) are syndemic in the U.S., thus primary care providers (PCPs) who treat OUD by prescribing buprenorphine can play key roles to advance HCV elimination targets. We compared HCV screening and treatment among PCPs who do and do not prescribe buprenorphine in Washington (WA) State.

Methods: This study utilized a cross-sectional survey of PCPs in WA State, designed to characterize HCV care delivery practices and experiences/attitudes toward HCV. In this study, the independent variable was self-reported buprenorphine prescribing, and the main outcomes were (1) guideline-concordant HCV screening and (2) directly providing treatment for HCV. We used descriptive statistics to describe respondent characteristics. We used logistic regression to assess the association between buprenorphine prescribing status and HCV screening and treatment outcomes.

Results: Our sample included 73 PCPs, of whom 55% prescribe buprenorphine. We found that 25% of buprenorphine prescribers directly treated HCV. There was over a 2x greater relative odds that buprenorphine prescribers would correctly screen for HCV relative to non-prescribers (OR = 2.24; 95% CI: 0.67-8.18, p = .20) and a nearly 2.5x greater relative odds that they would treat HCV relative to non-prescribers (OR = 2.42; 0.72-9.61; p = .17), although both findings were not statistically significant.

Conclusion: In a sample of PCPs in WA state, buprenorphine prescribers compared to non-prescribers appear more likely to screen for and directly treat HCV, yet only a minority treat HCV. Interventions are needed to enhance HCV guideline-concordant care among these and all PCPs on the frontlines of caring for persons with OUD.

查看原文本刊更多论文

丁丙诺啡处方者和非处方者的丙型肝炎护理交付实践：来自华盛顿州初级保健提供者的调查结果。

背景：丙型肝炎感染（HCV）和阿片类药物使用障碍（OUD）在美国是综合征，因此通过丁丙诺啡治疗OUD的初级保健提供者（pcp）可以在推进HCV消除目标方面发挥关键作用。我们比较了华盛顿州使用丁丙诺啡和不使用丁丙诺啡的pcp的HCV筛查和治疗情况。方法：本研究对西澳州的pcp进行了横断面调查，旨在描述HCV护理服务实践和经验/对HCV的态度。在本研究中，自变量为自我报告的丁丙诺啡处方，主要结果为(1)符合指南的HCV筛查和(2)直接提供HCV治疗。我们使用描述性统计来描述被调查者的特征。我们使用逻辑回归来评估丁丙诺啡处方状况与HCV筛查和治疗结果之间的关系。结果：我们的样本包括73名pcp，其中55%的pcp处方丁丙诺啡。我们发现25%的丁丙诺啡处方者直接治疗HCV。丁丙诺啡处方者正确筛查HCV的相对几率比非处方者高2倍以上（OR = 2.24; 95% CI: 0.67-8.18, p =）。20)，与非处方者相比，他们治疗HCV的相对几率高出近2.5倍(OR = 2.42; 0.72-9.61; p =。17)，尽管这两个结果在统计学上都不显著。结论：在西澳州的pcp样本中，丁丙诺啡处方者比非处方者更有可能筛查和直接治疗HCV，但只有少数人治疗HCV。需要采取干预措施，以加强这些和所有在OUD患者护理第一线的pcp之间符合HCV指南的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Addiction Science & Clinical Practice Psychology-Clinical Psychology

CiteScore

3.90

自引率

10.80%

发文量

审稿时长

28 weeks

期刊介绍： Addiction Science & Clinical Practice provides a forum for clinically relevant research and perspectives that contribute to improving the quality of care for people with unhealthy alcohol, tobacco, or other drug use and addictive behaviours across a spectrum of clinical settings. Addiction Science & Clinical Practice accepts articles of clinical relevance related to the prevention and treatment of unhealthy alcohol, tobacco, and other drug use across the spectrum of clinical settings. Topics of interest address issues related to the following: the spectrum of unhealthy use of alcohol, tobacco, and other drugs among the range of affected persons (e.g., not limited by age, race/ethnicity, gender, or sexual orientation); the array of clinical prevention and treatment practices (from health messages, to identification and early intervention, to more extensive interventions including counseling and pharmacotherapy and other management strategies); and identification and management of medical, psychiatric, social, and other health consequences of substance use. Addiction Science & Clinical Practice is particularly interested in articles that address how to improve the quality of care for people with unhealthy substance use and related conditions as described in the (US) Institute of Medicine report, Improving the Quality of Healthcare for Mental Health and Substance Use Conditions (Washington, DC: National Academies Press, 2006). Such articles address the quality of care and of health services. Although the journal also welcomes submissions that address these conditions in addiction speciality-treatment settings, the journal is particularly interested in including articles that address unhealthy use outside these settings, including experience with novel models of care and outcomes, and outcomes of research-practice collaborations. Although Addiction Science & Clinical Practice is generally not an outlet for basic science research, we will accept basic science research manuscripts that have clearly described potential clinical relevance and are accessible to audiences outside a narrow laboratory research field.